Q1 2023

Source filing unavailable

Q1 2023 · —

Revenue—

Net Income

-$39.81M

N/M vs Q1 2022

EPS Diluted

-$0.23

N/M vs Q1 2022

Operating Income-$39,148,000N/M

Operating Cash Flow-$42,419,000—

Free Cash Flowderived-$46,041,000—

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	—	—	$269.00K	$338.00K
Net Income	-$39.81M	-$37.06M	-$33.27M	-$29.87M
EPS Diluted	-$0.23	-$0.41	-$0.53	-$0.60

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR